Literature DB >> 28432476

Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease.

Esteban Sáez-González1, Inés Moret2,3,4, Diego Alvarez-Sotomayor2, Francia Carolina Díaz-Jaime2, Elena Cerrillo2,3, Marisa Iborra2,3,4, Pilar Nos2,3,4, Belén Beltrán2,3,4.   

Abstract

Ulcerative colitis and Crohn's disease are the two main forms of inflammatory bowel disease (IBD). The study of immunological pathways involved in the onset of IBD is of fundamental importance to identify potential biological markers of disease activity and specific targets for therapy. Removing excess and activated circulating leukocytes with adsorptive cytapheresis has been shown to be a potentially effective treatment for patients with an inflamed bowel. Adsorptive cytapheresis is a non-pharmacological approach for active IBD, in which known sources of inflammatory cytokines such as activated myeloid lineage leucocytes are selectively depleted from the circulatory system. The decrease in inflammatory load caused by removing these cells is thought to enhance drug therapy and thereby promote disease remission. The benefit of cytapheresis appears to rest upon its ability to reduce levels of certain immune cell populations; however, whether this depletion results in further changes in lymphocyte populations and cytokine production needs further clarification. In this review, we aim to summarize existing evidence on the role of cytapheresis in patients with IBD, its effect on cytokine levels and cellular populations, and to discuss its potential impact on disease activity.

Entities:  

Keywords:  Cytapheresis; Cytokines; Granulocyte and monocyte apheresis; Inflammatory bowel disease; Leukocytapheresis; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 28432476     DOI: 10.1007/s10620-017-4577-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  51 in total

Review 1.  Cytapheresis in inflammatory bowel diseases: current evidence and perspectives.

Authors:  Silvio Danese; Erika Angelucci; Tommaso Stefanelli; Paolo Omodei; Carmelo Luigiano; Silvia Finazzi; Nico Pagano; Alessandro Repici; Maurizio Vecchi; Alberto Malesci
Journal:  Digestion       Date:  2008-04-01       Impact factor: 3.216

Review 2.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 3.  PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Man Cai Wang; Ling Yi Zhang; Wei Han; Yuan Shao; Mo Chen; Rui Ni; Gen Nian Wang; Feng Xian Wei; Ya Wu Zhang; Xiao Dong Xu; You Cheng Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

4.  Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.

Authors:  Akira Andoh; Atsuhiro Ogawa; Ken-ichi Kitamura; Osamu Inatomi; Sanae Fujino; Tomoyuki Tsujikawa; Masaya Sasaki; Keiichi Mitsuyama; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

5.  Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Ken Takeuchi; Takayuki Iida; Nobuhito Kashiwagi; Abby R Saniabadi; Isao Matsushita; Yoshihiko Sato; Naoki Kasuga; Toshihiro Nakamura
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

6.  A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice.

Authors:  Yoko Yokoyama; Katsuyoshi Matsuoka; Taku Kobayashi; Koji Sawada; Tateshi Fujiyoshi; Takafumi Ando; Yoshifumi Ohnishi; Tetsuya Ishida; Masashi Oka; Masahiro Yamada; Takashi Nakamura; Tomoko Ino; Toyoko Numata; Hirofumi Aoki; Jun-Ichi Sakou; Masahiro Kusada; Tomoki Maekawa; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2014-02-18       Impact factor: 9.071

7.  Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis.

Authors:  Nobuhito Kashiwagi; Kazuhito Sugimura; Hirobumi Koiwai; Hironori Yamamoto; Toshikazu Yoshikawa; Abby R Saniabadi; Masakazu Adachi; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

8.  Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes.

Authors:  Gabriella Passacquale; Padman Vamadevan; Luis Pereira; Colleen Hamid; Valerie Corrigall; Albert Ferro
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

9.  Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results.

Authors:  Axel Dignass; Ayesha Akbar; Ailsa Hart; Sreedhar Subramanian; Gilles Bommelaer; Daniel C Baumgart; Jean-Charles Grimaud; Guillaume Cadiot; Richard Makins; Syed Hoque; Guillaume Bouguen; Bruno Bonaz
Journal:  J Crohns Colitis       Date:  2016-01-27       Impact factor: 9.071

10.  An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.

Authors:  Naoki Yoshimura; Yoko Yokoyama; Katsuyoshi Matsuoka; Hiroki Takahashi; Ryuichi Iwakiri; Takayuki Yamamoto; Tomoo Nakagawa; Takumi Fukuchi; Satoshi Motoya; Reiko Kunisaki; Shingo Kato; Fumihito Hirai; Yoh Ishiguro; Satoshi Tanida; Sakiko Hiraoka; Keiichi Mitsuyama; Shunji Ishihara; Shinji Tanaka; Michiro Otaka; Taro Osada; Takashi Kagaya; Yasuo Suzuki; Hiroshi Nakase; Hiroyuki Hanai; Kenji Watanabe; Nobuhito Kashiwagi; Toshifumi Hibi
Journal:  BMC Gastroenterol       Date:  2015-11-19       Impact factor: 3.067

View more
  3 in total

Review 1.  An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.

Authors:  Francesca Ferretti; Rosanna Cannatelli; Maria Camilla Monico; Giovanni Maconi; Sandro Ardizzone
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

Review 2.  Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease.

Authors:  Farah Yasmin; Hala Najeeb; Unaiza Naeem; Abdul Moeed; Thoyaja Koritala; Salim Surani
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

3.  Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy.

Authors:  Na Li; Jingwei Mao; Haiying Tang; Lei Zhu; Xiaoyan Tan; Jian Bi; Hao Wu; Xiuli Chen; Yingde Wang
Journal:  J Clin Apher       Date:  2020-05-07       Impact factor: 2.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.